Results for tag: "Intravitreal Injectables"

Intravitreal injectables are specialized medications injected directly into the vitreous near the retina at the back of the eye, primarily used for treating conditions such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions. Within the broader category of infusions and injectables, intravitreal injections are a niche but important segment due to the peculiarities of ocular diseases and the necessity of delivering treatments directly to the affected area to prevent vision loss. The administration of drugs through this route ensures higher concentrations at the target site, potentially reducing systemic exposure and side effects. The market for intravitreal injectables comprises a range of products, including anti-VEGF agents, corticosteroids, and biologics, which are designed to address various underlying causes of retinal diseases. Anti-VEGF agents, in particular, constitute a key class of therapy, as they inhibit the growth of abnormal blood vessels in the eye that can lead to vision impairment. Manufacturers operate within a highly regulated space, with stringent requirements for product safety and efficacy due to the sensitive nature of ocular treatments. Some key players within the intravitreal injectables market include Regeneron Pharmaceuticals, which markets a well-known anti-VEGF product, and Genentech, a subsidiary of Roche, which also offers treatments for macular degeneration and other eye conditions. Allergan (now part of AbbVie) is another prominent name, with a portfolio that includes Show Less Read more